Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (36)	11/14/2007 4:00:47 PM
From: scaram(o)uche	Respond to of 117

Could be a Rosenwald "Genta-like" play, where he shakes out an offering at low-ball prices. CEO has an obligation to free himself from the toxic grip of Paramount.

To: scaram(o)uche who wrote (36)	11/14/2007 9:55:09 PM
From: fred hayes	Read Replies (1) \| Respond to of 117

"not pretty" looks to be putting it mildly. Looked at this awhile ago but lost track of the liquidity issue. As of 9.30 have more current liabilities than cash -- must be even worse by now. But 14.6 mil shares @ $1.55 gives mc of only $23 million. Two late stage drugs kinda-maybe look low risk, including Tamibarotine (already approved in Japan), covered by SPA, and should be okayed end of 2008. Next up "406" for CML nda target 1h 2009. Several hundred $ million peak sales potential for these 2 per IVPH. 2 other drugs with nda target in 2011. My big question: how much is the pipe worth. Looks like we'll know something very quickly? Something has to give here. Gotta think it's worth more than $23 mil. Sale of company? Or financing?